1
|
Singh A, Kumar V, Mishra A, Singh VK. Targeting the HIV-1 Tat and Human Tat Protein Complex through Natural
Products: An In Silico Docking and Molecular Dynamics Simulation
Approach. LETT DRUG DES DISCOV 2022. [DOI: 10.2174/1570180819666220330122542] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
Background:
Tat protein is considered essential for substantial HIV-1 replication, and is also
required to break HIV-1 latency, resulting in productive HIV replication. The multifaceted regulatory role
of HIV Tat and the fact that it is expressed in the early stages of HIV infection justify its potential as an
anti-HIV drug target.
Objective:
The present study was undertaken with the aim to target HIV-1 Tat protein with natural compounds
which could help in identifying potential inhibitors against HIV-1 Tat.
Methods:
In this study, we compared the binding of Tat protein and Human P-TEFb Tat protein complex
(TPC) with phyto-steroids and terpenes to evaluate their potential for HIV-1 treatment. The docking ability
of plant products with HIV-1 Tat and TPC was studied with respect to dissociation constant, geometric
shape complementary score, approximate interface area, and binding energy using Patch dock and
YASARA. Molecular dynamics simulation was set up to investigate the interactions of the natural compounds
with Tat protein and human tat protein complex (TPC).
Results:
The binding energy and dissociation constant of Diosgenin, Catharanthine and Ginkgolide A
with Tat and TPC were comparable to antiretroviral drugs, Maraviroc and Emtricitabine. The natural
products, Diosgenin, Ginkgolide A and Catharanthine, showed the highest binding energy and were stable
with Tat protein and TPC in the entire MD simulation run.
Conclusion:
The natural products, Diosgenin, Ginkgolide A and Catharanthine, showed highest binding
energy and were stable with Tat protein and TPC in the entire MD simulation run. The binding energy
and dissociation constant of Diosgenin, Catharanthine and Ginkgolide A with Tat and TPC were comparable
to antiretroviral drugs, Maraviroc and Emtricitabine.
Collapse
Affiliation(s)
- Anchal Singh
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, U.P., India
| | - Vipin Kumar
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, U.P., India
| | - Ayushi Mishra
- Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi 221005, U.P., India
| | - Vinay Kumar Singh
- Centre for
Bioinformatics, School of Biotechnology, Institute of Science, Banaras Hindu University, Varanasi 221005, U.P., India
| |
Collapse
|
2
|
Tevyashova AN, Shapovalova KS. Potential for the Development of a New Generation of Aminoglycoside Antibiotics. Pharm Chem J 2022; 55:860-875. [PMID: 35039693 PMCID: PMC8754558 DOI: 10.1007/s11094-021-02510-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2021] [Indexed: 11/29/2022]
Abstract
The present review summarizes recent publications devoted to aminoglycosides that study the main types of resistance to antibiotics of this class and the main directions of chemical modification aimed at overcoming the resistance or changing the spectrum of biological activity. Conjugates of aminoglycosides with various pharmacophores including amino acids, peptides, peptide nucleic acids, nucleic bases, and several other biologically active molecules and modifications resulting in other types of biological activity of this class of antibiotics are described. It is concluded that a promising research direction aimed at increasing the activity of antibiotics against resistant strains is the search for selective inhibitors of aminoglycoside-modifying enzymes. This would allow renewal of the use of antibiotics already meeting widespread resistance and would increase the potential of a new generation of antibiotics.
Collapse
Affiliation(s)
- A. N. Tevyashova
- G. F. Gause Institute of New Antibiotics, 11/1 B. Pirogovskaya St, Moscow, 119021 Russia
| | - K. S. Shapovalova
- G. F. Gause Institute of New Antibiotics, 11/1 B. Pirogovskaya St, Moscow, 119021 Russia
| |
Collapse
|
3
|
Aradi K, Di Giorgio A, Duca M. Aminoglycoside Conjugation for RNA Targeting: Antimicrobials and Beyond. Chemistry 2020; 26:12273-12309. [PMID: 32539167 DOI: 10.1002/chem.202002258] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2020] [Revised: 06/11/2020] [Indexed: 01/04/2023]
Abstract
Natural aminoglycosides are therapeutically useful antibiotics and very efficient RNA ligands. They are oligosaccharides that contain several ammonium groups able to interfere with the translation process in prokaryotes upon binding to bacterial ribosomal RNA (rRNA), and thus, impairing protein synthesis. Even if aminoglycosides are commonly used in therapy, these RNA binders lack selectivity and are able to bind to a wide number of RNA sequences/structures. This is one of the reasons for their toxicity and limited applications in therapy. At the same time, the ability of aminoglycosides to bind to various RNAs renders them a great source of inspiration for the synthesis of new binders with improved affinity and specificity toward several therapeutically relevant RNA targets. Thus, a number of studies have been performed on these complex and highly functionalized compounds, leading to the development of various synthetic methodologies toward the synthesis of conjugated aminoglycosides. The aim of this review is to highlight recent progress in the field of aminoglycoside conjugation, paying particular attention to modifications performed toward the improvement of affinity and especially to the selectivity of the resulting compounds. This will help readers to understand how to introduce a desired chemical modification for future developments of RNA ligands as antibiotics, antiviral, and anticancer compounds.
Collapse
Affiliation(s)
- Klara Aradi
- Université Côte d'Azur, CNRS, Institute of Chemistry of Nice (ICN), 06100, Nice, France
| | - Audrey Di Giorgio
- Université Côte d'Azur, CNRS, Institute of Chemistry of Nice (ICN), 06100, Nice, France
| | - Maria Duca
- Université Côte d'Azur, CNRS, Institute of Chemistry of Nice (ICN), 06100, Nice, France
| |
Collapse
|
4
|
Ying L, Zhu H, Fosso MY, Garneau-Tsodikova S, Fredrick K. Modified Aminoglycosides Bind Nucleic Acids in High-Molecular-Weight Complexes. Antibiotics (Basel) 2020; 9:antibiotics9020093. [PMID: 32098020 PMCID: PMC7168264 DOI: 10.3390/antibiotics9020093] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 02/17/2020] [Accepted: 02/18/2020] [Indexed: 12/05/2022] Open
Abstract
Aminoglycosides represent a large group of antibiotics well known for their ability to target the bacterial ribosome. In studying 6”-substituted variants of the aminoglycoside tobramycin, we serendipitously found that compounds with C12 or C14 linear alkyl substituents potently inhibit reverse transcription in vitro. Initial observations suggested specific inhibition of reverse transcriptase. However, further analysis showed that these and related compounds bind nucleic acids with high affinity, forming high-molecular weight complexes. Stable complex formation is observed with DNA or RNA in single- or double-stranded form. Given the amphiphilic nature of these aminoglycoside derivatives, they likely form micelles and/or vesicles with surface-bound nucleic acids. Hence, these compounds may be useful tools to localize nucleic acids to surfaces or deliver nucleic acids to cells or organelles.
Collapse
Affiliation(s)
- Lanqing Ying
- Department of Microbiology and Center for RNA Biology, The Ohio State University, Columbus, OH 43210-1292, USA; (L.Y.); (H.Z.)
| | - Hongkun Zhu
- Department of Microbiology and Center for RNA Biology, The Ohio State University, Columbus, OH 43210-1292, USA; (L.Y.); (H.Z.)
| | - Marina Y. Fosso
- Department of Pharmaceutical Sciences in the College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA; (M.Y.F.); (S.G.-T.)
| | - Sylvie Garneau-Tsodikova
- Department of Pharmaceutical Sciences in the College of Pharmacy, University of Kentucky, Lexington, KY 40536-0596, USA; (M.Y.F.); (S.G.-T.)
| | - Kurt Fredrick
- Department of Microbiology and Center for RNA Biology, The Ohio State University, Columbus, OH 43210-1292, USA; (L.Y.); (H.Z.)
- Correspondence: ; Tel.: +1-614-292-6679
| |
Collapse
|
5
|
Jin Y, Watkins D, Degtyareva NN, Green KD, Spano MN, Garneau-Tsodikova S, Arya DP. Arginine-linked neomycin B dimers: synthesis, rRNA binding, and resistance enzyme activity. MEDCHEMCOMM 2016; 7:164-169. [PMID: 26811742 PMCID: PMC4722958 DOI: 10.1039/c5md00427f] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
The nucleotides comprising the ribosomal decoding center are highly conserved, as they are important for maintaining translational fidelity. The bacterial A-site has a small base variation as compared with the human analogue, allowing aminoglycoside (AG) antibiotics to selectively bind within this region of the ribosome and negatively affect microbial protein synthesis. Here, by using a fluorescence displacement screening assay, we demonstrate that neomycin B (NEO) dimers connected by L-arginine-containing linkers of varying length and composition bind with higher affinity to model A-site RNAs compared to NEO, with IC50 values ranging from ~40-70 nM, and that a certain range of linker lengths demonstrates a clear preference for the bacterial A-site RNA over the human analogue. Furthermore, AG-modifying enzymes (AMEs), such as AG O-phosphotransferases, which are responsible for conferring antibiotic resistance in many types of infectious bacteria, demonstrate markedly reduced activity against several of the L-arginine-linked NEO dimers in vitro. The antimicrobial activity of these dimers against several bacterial strains is weaker than that of the parent NEO.
Collapse
Affiliation(s)
- Yi Jin
- Clemson University, Department of Chemistry, Clemson, SC, 29634, USA
| | | | | | - Keith D. Green
- University of Kentucky, Department of Pharmaceutical Sciences, 789 South Limestone Street, Lexington, KY, 40536-0596, USA. Fax: 859-257-7585; Tel: 859-218-1686
| | | | - Sylvie Garneau-Tsodikova
- University of Kentucky, Department of Pharmaceutical Sciences, 789 South Limestone Street, Lexington, KY, 40536-0596, USA. Fax: 859-257-7585; Tel: 859-218-1686
| | - Dev P. Arya
- Clemson University, Department of Chemistry, Clemson, SC, 29634, USA
- NUBAD, LLC, Greenville, SC, 29605, USA
| |
Collapse
|
6
|
Stelzer AC, Frank AT, Kratz JD, Swanson MD, Gonzalez-Hernandez MJ, Lee J, Andricioaei I, Markovitz DM, Al-Hashimi HM. Discovery of selective bioactive small molecules by targeting an RNA dynamic ensemble. Nat Chem Biol 2011; 7:553-9. [PMID: 21706033 PMCID: PMC3319144 DOI: 10.1038/nchembio.596] [Citation(s) in RCA: 201] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2010] [Accepted: 04/18/2011] [Indexed: 11/09/2022]
Abstract
Current approaches used to identify protein-binding small molecules are not suited for identifying small molecules that can bind emerging RNA drug targets. By docking small molecules onto an RNA dynamic ensemble constructed by combining NMR spectroscopy and computational molecular dynamics, we virtually screened small molecules that target the entire structure landscape of the transactivation response element (TAR) from HIV type 1 (HIV-1). We quantitatively predict binding energies for small molecules that bind different RNA conformations and report the de novo discovery of six compounds that bind TAR with high affinity and inhibit its interaction with a Tat peptide in vitro (K(i) values of 710 nM-169 μM). One compound binds HIV-1 TAR with marked selectivity and inhibits Tat-mediated activation of the HIV-1 long terminal repeat by 81% in T-cell lines and HIV replication in an HIV-1 indicator cell line (IC(50) ∼23.1 μM).
Collapse
Affiliation(s)
- Andrew C. Stelzer
- Department of Chemistry & Biophysics, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, USA
| | - Aaron T. Frank
- Department of Chemistry, University of California Irvine, 1102 Natural Sciences 2, Irvine, California 92697, USA
| | - Jeremy D. Kratz
- Department of Chemistry & Biophysics, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, USA
| | - Michael D. Swanson
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
| | - Marta J. Gonzalez-Hernandez
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
| | - Janghyun Lee
- Department of Chemistry & Biophysics, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, USA
| | - Ioan Andricioaei
- Department of Chemistry, University of California Irvine, 1102 Natural Sciences 2, Irvine, California 92697, USA
| | - David M. Markovitz
- Department of Internal Medicine, Division of Infectious Diseases, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
| | - Hashim M. Al-Hashimi
- Department of Chemistry & Biophysics, University of Michigan, 930 North University Avenue, Ann Arbor, Michigan 48109, USA
- Correspondence and requests for materials should be addressed to H. M. A. ()
| |
Collapse
|
7
|
Murakami T, Yamamoto N. Role of CXCR4 in HIV infection and its potential as a therapeutic target. Future Microbiol 2010; 5:1025-39. [DOI: 10.2217/fmb.10.67] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
Abstract
The chemokine receptors CCR5 and CXCR4 are the two major coreceptors for HIV entry. Numerous efforts have been made to develop a new class of anti-HIV agents that target these coreceptors as an additional or alternative therapy to standard HAART. Among the CCR5 inhibitors developed so far, maraviroc is the first drug that has been approved by the US FDA for treating patients with R5 HIV-1. Although many CXCR4 inhibitors, some of which are highly active and orally bioavailable, have also been studied, they are still at preclinical stages or have been suspended during development. Importantly, the interaction between CXCR4 and its ligand SDF-1 is involved in various disease conditions, such as cancer cell metastasis, leukemia cell proliferation, rheumatoid arthritis and pulmonary fibrosis. Therefore, CXCR4 inhibitors have potential as novel therapeutics for the treatment of these diseases as well as HIV infection.
Collapse
Affiliation(s)
- Tsutomu Murakami
- AIDS Research Center, National Institute of Infectious Diseases, 1–23–1 Toyama, Shinjuku-ku, Tokyo 162–8640 Japan
| | - Naoki Yamamoto
- Department of Microbiology, Yong Loo Lin School of Medicine, National University of Singapore 5 Science Drive 2, Blk MD4A, Level 5, 117597 Singapore
| |
Collapse
|
8
|
Abstract
PURPOSE OF REVIEW One of the major problems in HIV chemotherapy is appearance of drug-resistant virus strains. Novel HIV intervention strategies are required and new targets must be considered. The nuclear export of intron-containing HIV-1 mRNA is an essential step in the viral replication cycle and is a prospective antiviral target. This nucleocytoplasmic transport is mediated by the viral protein Rev. Rev binds as a multimeric complex to the viral mRNA and exports it to the cytoplasm exploiting the CRM1-mediated cellular machinery. Inhibitors acting on the interface between virus and cell could overcome the problems of drug resistance against virus-specific treatments. These drugs have an added value in combination therapy as they are expected to be less prone to virus-drug resistance selection, but they are likely to be more cytotoxic. RECENT FINDINGS We will discuss the therapeutic approaches aimed at interfering with Rev function, both now and likely in the future, and the recent attempts that have been undertaken to design small molecules against this target. SUMMARY Recent approaches provide leads for development of new compounds. A better understanding of the mechanism of Rev action and its interaction with the cellular transport pathway is required to identify and rationally design novel strategies that may have potential for future antiretroviral intervention.
Collapse
|
9
|
Teixeira C, Serradji N, Maurel F, Barbault F. Docking and 3D-QSAR studies of BMS-806 analogs as HIV-1 gp120 entry inhibitors. Eur J Med Chem 2009; 44:3524-32. [DOI: 10.1016/j.ejmech.2009.03.028] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2008] [Revised: 01/27/2009] [Accepted: 03/19/2009] [Indexed: 10/21/2022]
|
10
|
Synthesis and evaluation of novel neamine derivatives effectively targeting to RNA. Bioorg Med Chem Lett 2009; 19:2103-6. [DOI: 10.1016/j.bmcl.2009.03.021] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2008] [Revised: 02/18/2009] [Accepted: 03/09/2009] [Indexed: 11/21/2022]
|
11
|
Tamamura H, Tsutsumi H, Nomura W, Tanaka T, Fujii N. A future perspective on the development of chemokine receptor CXCR4 antagonists. Expert Opin Drug Discov 2008; 3:1155-66. [DOI: 10.1517/17460441.3.10.1155] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Lapidot A, Berchanski A, Borkow G. Insight into the mechanisms of aminoglycoside derivatives interaction with HIV-1 entry steps and viral gene transcription. FEBS J 2008; 275:5236-57. [PMID: 18803669 DOI: 10.1111/j.1742-4658.2008.06657.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
In recent years, based on peptide models of HIV-1 RNA binding, NMR structures of Tat-responsive element-ligand complexes and aminoglycoside-RNA interactions, and HIV-1 Tat structure, we have designed and synthesized aminoglycoside-arginine conjugates (AACs) and aminoglycoside poly-arginine conjugates (APACs), to serve as Tat mimetics. These novel molecules inhibit HIV-1 infectivity with 50% effective concentration values in the low micromolar range, the most potent compounds being the hexa-arginine-neomycin B and nona-D-arginine-neomycin conjugates. Importantly, these compounds, in addition to acting as Tat antagonists, inhibit HIV-1 infectivity by blocking several steps in HIV-1 cell entry. The AACs and APACs inhibit HIV-1 cell entry by interacting with gp120 at the CD4-binding site, by interacting with CXCR4 at the binding site of the CXCR4 mAb 12G5, and apparently by interacting with transient structures of the ectodomain of gp41. In the current review, we discuss the mechanisms of anti-HIV-1 activities of these AACs, APACs and other aminoglycoside derivatives in detail. Targeting several key processes in the viral life cycle by the same compound not only may increase its antiviral efficacy, but more importantly, may reduce the capacity of the virus to develop resistance to the compound. AACs and APACs may thus serve as leading compounds for the development of multitargeting novel HIV-1 inhibitors.
Collapse
Affiliation(s)
- Aviva Lapidot
- Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, Israel.
| | | | | |
Collapse
|
13
|
Lapidot A, Peled A, Berchanski A, Pal B, Kollet O, Lapidot T, Borkow G. NeoR6 inhibits HIV-1-CXCR4 interaction without affecting CXCL12 chemotaxis activity. Biochim Biophys Acta Gen Subj 2008; 1780:914-20. [DOI: 10.1016/j.bbagen.2008.03.011] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/24/2007] [Revised: 03/05/2008] [Accepted: 03/07/2008] [Indexed: 11/30/2022]
|
14
|
Tamamura H, Tsutsumi H, Nomura W, Fujii N. Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing. PERSPECTIVES IN MEDICINAL CHEMISTRY 2008; 2:1-9. [PMID: 19787093 PMCID: PMC2746577 DOI: 10.4137/pmc.s422] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Seven transmembrane (7TM) G-protein-coupled receptor (GPCR) families are important targets for drug discovery, and specific antagonists for GPCR can accelerate research in the field of medicinal chemistry. The chemokine receptor CXCR4 is a GPCR that possesses a unique ligand CXCL12/stromal cell-derived factor-1 (SDF-1). The interaction between CXCL12 and CXCR4 is essential for the migration of progenitor cells during embryonic development of the cardiovascular, hemopoietic and central nervous systems, and also involved in several intractable disease processes, including HIV infection, cancer cell metastasis, progression of acute and chronic leukemias, rheumatoid arthritis and pulmonary fibrosis. Thus, CXCR4 may be an important therapeutic target in all of these diseases, and various CXCR4 antagonists have been proposed as potential drugs. Fourteen-mer peptides, T140 and its analogs, and downsized cyclic pentapeptides have been developed by us as potent CXCR4 antagonists. This article describes the development of a number of specific CXCR4 antagonists in our laboratory, including downsizing.
Collapse
Affiliation(s)
- Hirokazu Tamamura
- Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Chiyoda-ku, Tokyo 101-0062, Japan
| | | | | | | |
Collapse
|
15
|
Tsutsumi H, Tanaka T, Ohashi N, Masuno H, Tamamura H, Hiramatsu K, Araki T, Ueda S, Oishi S, Fujii N. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents. Biopolymers 2007; 88:279-89. [PMID: 17167792 DOI: 10.1002/bip.20653] [Citation(s) in RCA: 45] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
The chemokine receptor CXCR4 possesses multiple critical functions in normal and pathologic physiology. CXCR4 is a G-protein-coupled receptor that transduces signals of its endogenous ligand, the chemokine CXCL12 (stromal cell-derived factor-1, SDF-1). The interaction between CXCL12 and CXCR4 plays an important role in the migration of progenitors during embryologic development of the cardiovascular, hemopoietic, central nervous systems, and so on. This interaction is also known to be involved in several intractable disease processes, including HIV infection, cancer cell metastasis, leukemia cell progression, rheumatoid arthritis (RA), and pulmonary fibrosis. It is conjectured that this interaction may be a critical therapeutic target in all of these diseases, and several CXCR4 antagonists have been proposed as potential drugs. Fourteen-mer peptides, T140 and its analogues, were previously developed in our laboratory as specific CXCR4 antagonists that were identified as HIV-entry inhibitors, anti-cancer-metastatic agents, anti-chronic lymphocytic/acute lymphoblastic leukemia agents, and anti-RA agents. Cyclic pentapeptides, such as FC131 [cyclo(D-Tyr-Arg-Arg-L-3-(2-naphthyl)alanine-Gly)], were also previously found as CXCR4 antagonist leads based on pharmacophores of T140. This review article describes the elucidation of multiple functions of CXCR4 antagonists and the development of a number of low-molecular weight CXCR4 antagonists involving FC131 analogues and other compounds with different scaffolds including linear-type structures.
Collapse
Affiliation(s)
- Hiroshi Tsutsumi
- Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo, Japan
| | | | | | | | | | | | | | | | | | | |
Collapse
|
16
|
Berchanski A, Lapidot A. Prediction of HIV-1 entry inhibitors neomycin-arginine conjugates interaction with the CD4-gp120 binding site by molecular modeling and multistep docking procedure. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES 2007; 1768:2107-19. [PMID: 17560540 DOI: 10.1016/j.bbamem.2007.04.017] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2006] [Revised: 04/04/2007] [Accepted: 04/19/2007] [Indexed: 10/23/2022]
Abstract
Developing of multi-target HIV-1 entry inhibitors represents an important avenue of drug therapy. Two such inhibitors are hexa-arginine-neomycin-conjugate (NeoR6) and nona-d-arginine-neomycin-conjugate (Neo-r9). Our findings that NeoR6-resistant mutations appear in the gp120 constant regions; and NeoR6 is not CCR5 antagonist, but inhibits CXCR4 and CCR5 HIV-1 using isolates, led us to suggest that NeoR6 may inhibit HIV-1 entry by interfering with the CD4-gp120 binding. To support this notion, we constructed a homology model of unliganded HIV-1(IIIB) gp120 and docked NeoR6 and Neo-r9 to it, using a multistep docking procedure: geometric-electrostatic docking by MolFit; flexible ligand docking by Autodock3 and final refinement of the obtained complexes by Discover3. Binding free energies were calculated by MM-PBSA methodology. The model predicts competitive inhibition of CD4-gp120 binding by NeoR6 and Neo-r9. We determined plausible binding sites between constructed CD4-bound gp120 trimer and homology modeled membranal CXCR4, and tested NeoR6 and Neo-r9 interfering with this interaction. These models support our notion that another mechanism of anti-HIV-1 activity of NeoR6 is inhibition of gp120-CXCR4 binding. These structural models and interaction of NeoR6 and Neo-r9 with gp120 and CXCR4 provide a powerful approach for structural based drug design for selective targeting of HIV-1 entry and/or for inhibition of other retroviruses with similar mechanism of entry.
Collapse
Affiliation(s)
- Alexander Berchanski
- Department of Organic Chemistry, The Weizmann Institute of Science, Rehovot, 76100, Israel
| | | |
Collapse
|
17
|
Tamamura H, Fujii N. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis. Expert Opin Ther Targets 2006; 9:1267-82. [PMID: 16300475 DOI: 10.1517/14728222.9.6.1267] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
CXCR4 is the receptor of the chemokine CXCL12, which is involved in progression and metastasis of several types of cancer cells, HIV infection and rheumatoid arthritis. The authors developed selective CXCR4 antagonists, T22 and T140, initially as anti-HIV agents, which inhibit T cell line-tropic (X4-) HIV-1 infection through their specific binding to CXCR4. Recently, T140 analogues have also been shown to inhibit CXCL12-induced migration of breast cancer cells, leukaemia T cells, pancreatic cancer cells, small cell lung cancer cells, chronic lymphocytic leukaemia B cells, pre-B acute lymphoblastic leukaemia cells and so on in vitro. Biostable T140 analogues significantly suppressed pulmonary metastasis of breast cancer cells and melanoma cells in mice. Furthermore, these compounds significantly suppressed the delayed-type hypersensitivity response induced by sheep red blood cells and collagen-induced arthritis, which represent in vivo mouse models of arthritis. Thus, T140 analogues proved to be attractive lead compounds for chemotherapy of these problematic diseases. This article reviews recent research on T140 analogues, referring to several other CXCR4 antagonists.
Collapse
Affiliation(s)
- Hirokazu Tamamura
- Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University, Tokyo 101-0062, Japan.
| | | |
Collapse
|
18
|
Affiliation(s)
- Bert Willis
- Department of Chemistry, Clemson University, Clemson, SC 29634, USA
| | | |
Collapse
|
19
|
Lapidot A, Vijayabaskar V, Litovchick A, Yu J, James TL. Structure-activity relationships of aminoglycoside-arginine conjugates that bind HIV-1 RNAs as determined by fluorescence and NMR spectroscopy. FEBS Lett 2004; 577:415-21. [PMID: 15556620 DOI: 10.1016/j.febslet.2004.10.038] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2004] [Revised: 10/11/2004] [Accepted: 10/14/2004] [Indexed: 11/28/2022]
Abstract
We present here a new set of aminoglycoside-arginine conjugates (AACs) that are either site-specific or per-arginine conjugates of paromomycin, neamine, and neomycin B as well as their structure-activity relationships. Their binding constants (KD) for TAR and RRE RNAs, measured by fluorescence anisotropy, revealed dependence on the number and location of arginines in the different aminoglycoside conjugates. The binding affinity of the per-arginine aminoglycosides to TAR is higher than to RRE, and hexa-arginine neomycin B is the most potent binder (KD=5 and 23 nM, respectively). The 2D TOCSY NMR spectrum of the TAR monoarginine-neomycin complex reveals binding at the bulge region of TAR.
Collapse
Affiliation(s)
- Aviva Lapidot
- Department of Organic Chemistry, Weizmann Institute of Science, Rehovot 76100, Israel.
| | | | | | | | | |
Collapse
|
20
|
Borkow G, Lara HH, Lapidot A. Mutations in gp41 and gp120 of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate. Biochem Biophys Res Commun 2004; 312:1047-52. [PMID: 14651977 DOI: 10.1016/j.bbrc.2003.11.011] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Aminoglycoside-arginine conjugates (AACs) inhibit HIV-1 replication and act as Tat antagonists. AACs compete with monoclonal antibody binding to CXCR4, compete with SDF-1alpha and HIV-1 gp120 cellular uptake, indicating that they interfere with initial steps of HIV-1 infection. We here present the selection of HIV-1 isolates resistant to hexa-arginine neomycin B conjugate (NeoR6), the most potent anti-HIV-1 AAC. We found in the NeoR6-resistant isolates the following mutations in gp120: I339T in the C3 region, S372L in the V4 region, and Q395K in the C4 region; and in gp41: S668R and F672Y in the 'heptad repeat' 2 (HR2) region. These findings strongly suggest that NeoR6 obstructs HIV-1 replication by interfering with the fusion step, dependent on both conformational changes in gp120 following CD4 and CXCR4 interaction, as well as by conformational changes in gp41 induced by HR1 and HR2 interaction. The AACs may thus represent a novel family of fusion inhibitors.
Collapse
Affiliation(s)
- Gadi Borkow
- Department of Organic Chemistry, The Weizmann Institute of Science, 76100, Rehovot, Israel
| | | | | |
Collapse
|
21
|
Borkow G, Vijayabaskar V, Lara HH, Kalinkovich A, Lapidot A. Structure–activity relationship of neomycin, paromomycin, and neamine–arginine conjugates, targeting HIV-1 gp120–CXCR4 binding step. Antiviral Res 2003; 60:181-92. [PMID: 14638394 DOI: 10.1016/s0166-3542(03)00156-6] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
We have recently designed and synthesized aminoglycoside-arginine conjugates (AACs) as potential anti-HIV-1 agents. AACs exert a number of activities related to Tat antagonism. We here present a new set of AACs, conjugates of neomycin B, paromomycin, and neamine with different number of arginines (1-6), their (a) uptake by human T-cell lines, (b) antiviral activities, (c) competition with monoclonal antibody (mAb) 12G5 binding to CXCR4, (d) competition with stromal cell-derived factor-1 (SDF-1alpha) binding to CXCR4, and (e) competition with HIV-1 coat protein gp120 cell penetration. The appearance of mutations in HIV-1 gp120 gene in AACs resistant HIV-1 isolates, supports that AACs inhibit HIV-1 infectivity via interference of gp120-CXCR4 interaction. Our results point that the most potent AACs is the hexa-arginine-neomycin conjugate, the other multi-arginine-aminoglycoside conjugates are less active, and the mono-arginine conjugates display the lowest activity. Our studies demonstrate that, in addition to the core, the number of arginines attached to a specific aminoglycoside, are also important in the design of potent anti-HIV agents. The AACs play an important role, not only as HIV-1 RNA binders but also as inhibitors of viral entry into human cells.
Collapse
Affiliation(s)
- Gadi Borkow
- Department of Organic Chemistry, Weizmann Institute of Science, 76100 Rehovot, Israel
| | | | | | | | | |
Collapse
|
22
|
MESH Headings
- Aminoglycosides/pharmacology
- Anti-Bacterial Agents/pharmacology
- Binding Sites
- Drug Delivery Systems
- Models, Molecular
- RNA/chemistry
- RNA/metabolism
- RNA, Catalytic/chemistry
- RNA, Catalytic/metabolism
- RNA, Ribosomal, 16S/chemistry
- RNA, Ribosomal, 16S/drug effects
- RNA, Ribosomal, 16S/metabolism
- Substrate Specificity
- Technology, Pharmaceutical
- Water/chemistry
Collapse
Affiliation(s)
- Quentin Vicens
- Institut de Biologie Moléculaire et Cellulaire du CNRS, Modélisation et simulations des Acides Nucléiques, UPR 9002, Université Louis Pasteur, 15 rue René Descartes, 67084 Strasbourg, France
| | | |
Collapse
|
23
|
Catani MV, Corasaniti MT, Ranalli M, Amantea D, Litovchick A, Lapidot A, Melino G. The Tat antagonist neomycin B hexa-arginine conjugate inhibits gp-120-induced death of human neuroblastoma cells. J Neurochem 2003; 84:1237-45. [PMID: 12614324 DOI: 10.1046/j.1471-4159.2003.01620.x] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Several patients with acquired immunodeficiency syndrome (AIDS) develop neurological complications, which are referred to as human immunodeficiency virus (HIV)-associated dementia (HAD). The HIV-1 coat glycoprotein gp-120 has been proposed as the major etiologic agent for neuronal loss reported postmortem in the brain of AIDS patients. Chemokine receptors may play a role in gp-120-triggered neurotoxicity, both in vitro and in vivo, thus being an intriguing target for developing therapeutic strategies aimed to prevent or reduce neuronal damage occurring during HIV infection. We have previously shown that human CHP100 neuroblastoma cells express CXCR4 and CCR5 chemokine receptors and that interaction between gp-120 and these receptors contributes to cytotoxicity elicited by the protein. Here, we examined the neuroprotective potential of neomycin B hexa-arginine conjugate (NeoR), a recently synthesized compound with anti-HIV activity. We found that gp-120-triggered death is significantly reduced by NeoR, and this protective effect seems related to the ability of NeoR to interact with CXCR4 receptors. The ability of NeoR to cross the blood-brain barrier, as demonstrated in mice by systemic administration of the fluorescein conjugate drug, makes this compound a powerful and attractive therapeutic agent.
Collapse
Affiliation(s)
- Maria Valeria Catani
- Department of Experimental Medicine, University of Rome Tor Vergata, Rome, Italy
| | | | | | | | | | | | | |
Collapse
|
24
|
Kalinkevich AN, Sukhodub LF. Interactions between aminoglycoside antibiotics and carbohydrates studied by 252Cf plasma desorption mass spectrometry. RAPID COMMUNICATIONS IN MASS SPECTROMETRY : RCM 2003; 17:2370-2372. [PMID: 14558141 DOI: 10.1002/rcm.1191] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/24/2023]
|
25
|
Abstract
Due to the development of HIV-1 resistance to current antiviral drugs and the known toxicity of many of these drugs, there is a clear need to identify and develop novel compounds for use in the treatment of HIV-1 infected patients. The HIV-1 regulatory proteins, Tat and Rev, are required for HIV-1 replication and therefore represent two important viral targets for drug development. Novel drugs that target these proteins would increase the number of available treatment strategies for HIV-1 infection. This could result in better combination therapies in which many different viral targets could be inhibited simultaneously, thereby decreasing the likelihood of selecting for drug-resistant viruses. This review outlines many of the ways that Tat and Rev can be targeted for drug development, describes recently reported lead compounds as inhibitors of these proteins and discusses strategies for implementing drug screens for identifying novel inhibitors.
Collapse
Affiliation(s)
- Roger G Ptak
- Infectious Disease Research Department, Southern Research Institute, 431 Aviation Way, Frederick, Maryland 21701, USA.
| |
Collapse
|